Cytomegalovirus (HHV-5) Infections Pipeline Review Market Growth & Analysis Report 2015 Radiant Insights, Inc
Summary Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015 Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Summary
Radiant Insights's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/cytomegalovirus-hhv-5-infections-pipeline-review-h2-2015
Radiant Insights's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Radiant Insights's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Radiant Insights's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Small Molecules to Activate Sirtuin for Viral <strong>Infections</strong> - Drug Profile 122<br />
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV <strong>Infections</strong> - Drug Profile 123<br />
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious<br />
Diseases - Drug Profile 124<br />
Small Molecules to Inhibit Na+/K+ ATPase for Human <strong>Cytomegalovirus</strong> <strong>Infections</strong> - Drug Profile<br />
125<br />
TRL-345 - Drug Profile 126<br />
V-160 - Drug Profile 127<br />
Vacc-CMV - Drug Profile 128<br />
Vaccine for <strong>Cytomegalovirus</strong> Infection and Glioblastoma Multiforme - Drug Profile 129<br />
VBI-1501A - Drug Profile 130<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/cytomegalovirushhv-5-infections-pipeline-review-h2-<strong>2015</strong><br />
Viralym-C - Drug Profile 131<br />
Viroprev - Drug Profile 132<br />
VPM-2001 - Drug Profile 133<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Recent <strong>Pipeline</strong> Updates 134<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Dormant Projects 154<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Discontinued Products 158<br />
<strong>Cytomegalovirus</strong> (<strong>HHV</strong>-5) <strong>Infections</strong> - Product Development Milestones 159<br />
Featured News & Press Releases 159<br />
Appendix 168<br />
Methodology 168<br />
Coverage 168<br />
Secondary Research 168<br />
Primary Research 168<br />
Expert Panel Validation 168<br />
Contact Us 168<br />
Disclaimer 169
Change language